RxDoctor Payments Data

Maryellen Pace, MD

Urology · Greensboro, NCNPI 1134411390

Payments from drug & device makers

$3,101in general payments, 2019–2025

Across 154 payments — averaging $20.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$999
  • Merck$322
  • Dentsply IH Inc.$174
  • AstraZeneca$157
  • AbbVie$155
  • Laborie Medical Technologies Corp.$154
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,101100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,101 in reported general payments places this provider in the 50th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$92,636
Medicare patients
252
Services billed
3,268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron205$137,395
GemtesaVibegron79$66,977
Estradiol160$10,543
Tamsulosin Hcl387$6,211
Trospium Chloride ErTrospium Chloride17$5,218
Methenamine Hippurate62$3,690
Testosterone12$2,664
NitrofurantoinNitrofurantoin Macrocrystal29$1,699
Finasteride92$1,489
Trimethoprim22$1,171
Cephalexin85$1,013
Alfuzosin Hcl ErAlfuzosin Hcl27$457
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst38$454
Testosterone Cypionate17$224
Ciprofloxacin Hcl16$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$108$137,395205 claims
Sumitomo Pharma America, Inc.Gemtesa$104$66,97779 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 434 urology providers in North Carolina.

Other urology in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →